S100 protein as neutrophil activator for alleviating neutropenia in cancer treatment
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Dec 15, 2009
Grant Date -
Dec 14, 2006
app pub date -
Mar 25, 2004
filing date -
Mar 28, 2003
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
The present invention relates to a method and composition for inducing lymphocyte proliferation and migration, and for reducing the risks of microbial infections in patients immuno-suppressed. The present invention particularly relates to the use of S100 protein, such as MRP, to induce the proliferation, differentiation and release of immune cells from bone marrow. More particularly, S100A8, S100A9, S100A12 and S100A8/A9 are administered to patients with lowered neutrophil blood concentrations.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully